NIKKEI 225
38,913.48 +296.38 (+0.77%) HANG SENG
18,948.10 -247.50 (-1.29%) CRUDE OIL
77.16 -0.41 (-0.53%) GOLD FUTURES
2,372.90 -20.00 (-0.84%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,445.17 -517.48 (-0.94%)
ATOS Sep 2024 1.000 call
| Previous close | 0.7500 |
| Open | 0.6500 |
| Bid | 0.6000 |
| Ask | 2.9000 |
| Strike | 1.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.6500 - 0.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 116 |
ZacksAtossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?
Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
GlobeNewswireAtossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person
- GlobeNewswire
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Ato
